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forms was available for 77 patients. 
PCR results were available for 57 
patients and conﬁ  rmed the diagnosis 
for 39. Patient ages ranged from 2 to 
72 years; 40 (52%) patients were <15 
years of age. The male/female ratio 
was 0.83. For 44 (57%) of the patients, 
Buruli ulcer was a new diagnosis. In 
addition, 56 (73%) patients had an 
ulcerative lesion, and 21 (37%) of 
these had lesions >5 cm. The lesions 
were located on the lower arm for 
41 (53%) patients, upper arm for 28 
(36%) patients, chest and/or back for 
7 (9%) patients, and perineal region 
for 1 (1%) patient. 
Depending on the type of lesion, 
the length of hospitalization ranged 
from 1 to 352 days (median 31 days). 
The longest hospitalization was almost 
1 year; the patient was a child who had 
severe lesions and lived in conditions 
in which adequate wound care and 
follow-up after hospital discharge 
were unlikely.
In Gabon, the available data on 
Buruli ulcer come mainly from surgical 
wards in areas where prevalence is 
high. A national survey of hospital 
registration data in 2005 detected 3 
cases in Ngounie Province in southern 
Gabon and 5 cases in Woleu-Ntem 
Province in northern Gabon. All cases 
are thought to have been acquired 
locally, thus establishing the existence 
of 2 previously unknown foci (U. 
Ateba Ngoa et al., unpub. data).
Buruli ulcer has a strong 
economic effect on the community 
and health facilities. For example, in 
2010, management of the disease at 
the Albert Schweitzer Hospital cost an 
estimated 554–1,660 euros per person, 
not including drug costs (7). In 2009, 
African countries where Buruli ulcer is 
endemic, including Gabon, signed the 
Cotonou Declaration (8). According to 
this declaration, these countries have 
committed themselves to ﬁ  ght Buruli 
ulcer by several measures, including 
assessing the magnitude of the disease 
and conducting surveillance. 
U.A.N. and A.A.A. were supported 
by the “Deutsch-Afrikanische Koopera-
tionsprojekte in der Infektiologie,” grant 
no. KR 1150/6-1.
Ulysse Ateba Ngoa, 
Gregoire K. Adzoda, 
Bayonne Manou Louis, 
Ayola Akim Adegnika, 
and Bertrand Lell
Author afﬁ  liations:  Albert  Schweitzer 
Hospital, Lambaréné, Gabon (U. Ateba 
Ngoa, G.K. Adzoda, A.A. Adegnika, B. Lell); 
Ministry of Health, Libreville, Gabon (B.M. 
Louis); University of Tübingen, Tübingen, 
Germany (U. Ateba Ngoa, A.A. Adegnika, B. 
Lell); and Leiden University Medical Center, 
Leiden, the Netherlands (A.A. Adegnika)
DOI: http://dx.doi.org/10.3201/eid1807.110613
References
  1.   Asiedu K, Raviglione MC, Scherpbier R, 
eds. Buruli ulcer: Mycobacterium ulcer-
ans infection. Geneva: World Health Or-
ganization; 2000.
  2.   Hotez  PJ,  Kamath  A.  Neglected  tropi-
cal diseases in sub-Saharan Africa: re-
view of their prevalence, distribution, 
and disease burden. PLoS Negl Trop Dis. 
2009;3:e412. http://dx.doi.org/10.1371/
journal.pntd.0000412
    3.   Minime-Lingoupou F, Beyam N, Zan-
danga G, Manirakiza A, N’Domackrah 
A, Njuimo S, et al. Buruli ulcer, Central 
African Republic. Emerg Infect Dis. 
2010;16:746–8.
  4.   Woringer F, Tulasne R, Trensz F. Large 
ulceration with bacillus paratubercu-
leux (Mycobacterium ulcerans?) [in 
French]. Bull Soc Fr Dermatol Syphiligr. 
1961;68:325–8.
  5.   Burchard GD, Bierther M. Buruli ulcer: 
clinical pathological study of 23 patients 
in. Lambaréné, Gabon. Trop Med Parasi-
tol. 1986;37:1–8.
  6.   Carayon A, Perleuis P, Honorat M, Blin 
E. Ulcères par mycobactéries en Af-
rique. Bull Soc Med Afr Noire Lang Fr. 
1968;13:670–9.
  7.   Yambounze Guimony HJ. Ulcere de Bu-
ruli, cout du suivi d’un malade a l’hôpital 
Albert Schweitzer. Mémoire de ﬁ  n de cy-
cle [thesis]. Libreville (Gabon): Libreville 
Institut de Gestion; 2010.
  8.   World  Health  Organization.  Cotonou 
Declaration on Buruli ulcer [cited 2010 
Sep 20]. http://www.who.int/neglected_
diseases/Benin_declaration_2009_eng_
ok.pdf
Address for correspondence: Bertrand Lell, 
Medical Research Unit, Albert Schweitzer 
Hospital, BP 118, Lambaréné, Gabon; email: 
bertrand.lell@uni-tuebingen.de
Ebola Virus 
Antibodies in 
Fruit Bats, Ghana, 
West Africa
To the Editor: Fruit bats are the 
presumptive reservoir hosts of Ebola 
viruses (EBOVs) (genus Ebolavirus, 
family Filoviridae). When transmitted 
to humans and nonhuman primates, 
EBOVs can cause hemorrhagic fevers 
with high case-fatality rates.  In 2008, 
we detected Zaire EBOV (ZEBOV) 
antibodies in a single migratory fruit 
bat (Eidolon helvum) from a roost in 
Accra, Ghana (1). This bat is common 
in sub-Saharan Africa and lives in 
large colonies, often in cities. The 
ﬂ  ight of an individual E. helvum bat 
during migration has been recorded as 
>2,500 km (2). 
To understand whether the single 
seropositive Eidolon helvum bat was 
evidence of EBOV circulation in the 
Greater Accra Region or elsewhere in 
sub-Saharan Africa, we tested serum 
of 88 nonmigratory fruit bats from 
the surrounding region of Ghana. 
Serum samples had been collected, 
as previously described (3,4), 
during May–June 2007 from fruit 
bats in woodland and tropical forest 
habitats in southern Ghana within 
180 km of Accra. Initial screening 
for EBOV antibodies was conducted 
by using ELISA with a 1:1 mixture 
of recombinant nucleoprotein (NP) 
of ZEBOV and Reston EBOV 
(REBOV). Proteins were expressed 
in an Escherichia coli expression 
vector with a polyhistadine tag (1,5). 
Samples with optical density (OD) 
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readings 3-fold above the mean OD 
of 2 negative control serum samples 
were considered EBOV-positive by 
ELISA. ELISA-positive samples 
were tested separately (at a dilution 
of 1:50) for reactivity against ZEBOV 
and REBOV NPs by using ELISA 
and Western blot (WB) as described 
(1). Each sample with positive results 
from both assays was retested at 
increasing dilutions to determine the 
highest dilution (endpoint titer) at 
which it remained positive (>3-fold 
above the OD for EBOV-negative 
sera).
We detected EBOV antibodies 
(1:1 mixture of both NP antigens, 
OD>0.7) in serum samples from 32 
of 88 bats (10/27 Epomops franqueti, 
14/37  Epomophorus gambianus, 
7/16  Hypsignathus monstrosus, 1/4 
Nanonycteris veldkampii, and 0/1 
Epomops buettikoferi). When tested 
against an individual NP, 13 of the 
32 EBOV-positive serum samples 
were positive for EBOV (OD >0.50). 
Of those 13 EBOV-positive samples, 
9 were ZEBOV-positive only (from 
3  E. franqueti, 4 E. gambianus, 
and 2 H. monstrosus bats), 3 were 
REBOV-positive only (from 2 E. 
gambianus and 1 H. monstrosus bats), 
and 1 sample from an E. gambianus 
bat was positive for both ZEBOV 
and REBOV. Seven samples that 
the EBOV NP ELISA identiﬁ  ed  as 
positive were also positive by WB 
(Table). Each WB-positive serum 
sample was positive for the EBOV 
antigen that it had been most reactive 
against in the ELISA: 5 WB test 
results were positive for ZEBOV (2 of 
those samples also bound to REBOV), 
and 2 bound to REBOV only. Serum 
samples with positive OD values 
at endpoint dilutions >1:50 were 
deﬁ  nitively positive by WB; whereas 
those with positive OD values at and 
endpoint dilution of 1:50 only could 
be positive, negative, or equivocal by 
WB (Table).
Previous serum and viral antigen 
tests indicated the presence of 
EBOV among 2 of these bat species 
(E. franqueti and H. monstrosus) 
in Gabon, located in central Africa 
(6). Two others (E. gambianus and 
N. veldkampii) were not previously 
identiﬁ   ed as potential reservoirs. 
Because these are nonmigratory fruit 
bats, our ﬁ  ndings demonstrate that at 
least 1 serotype of EBOV circulates 
in bats in the Upper Guinean forest 
ecosystem in West Africa. These 
data might provide evidence that Taï 
Forest EBOV (TEBOV), formerly 
known as Côte d’Ivoire EBOV, 
circulates in this ecosystem among 
bats native to West Africa (7). EBOV 
antibody titers are highly correlated 
(8), but using TEBOV antigen might 
increase seroprevalence if TEBOV 
is the circulating virus. However, 
geographic location does not 
necessarily determine EBOV genetic 
relationships (9), and lack of cross-
reactivity between serum samples 
positive for REBOV and ZEBOV 
in our study might indicate that 
divergent viruses circulate regionally, 
given phylogenetic and antigenic 
relationships between EBOV species 
(7–10).
We detected a relatively high 
proportion of EBOV-seropositive 
fruit bats in a relatively small sample 
size of mixed species. We suggest 
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Table.  ZEBOV- and REBOV-specific results of ELISA and Western blot analysis of serum from Ebola virus–positive fruit bats, Ghana* 
Location, date, fruit bat species  Sex  Age 
ELISA OD (endpoint titer dilution)  Western blot† 
REBOV ZEBOV  REBOV  ZEBOV 
Sagyimase              
  May 29, 2007                
  Epomops  franqueti  F  A  0.11 (1:50)  0.53 (1:200)     +
  E.  franqueti  F  SI  0.08 (1:50)  0.62 (1:100)    +  + 
  Hypsignathus  monstrosus  F  A  0.12 (1:50)  1.08 (1:200)    +  + 
  H.  monstrosus  F  SI  1.11 (1:200)  0.17 (1:50)    +  
  H.  monstrosus  F A  0.15  0.71    
  H.  monstrosus‡ M SI  0.05  0.11    
May 30, 2007               
  E.  franqueti  F A  0.1§ 0.53§  +
Adoagyiri              
May 31, 2007               
  Epomophorus  gambianus  M A  0.59  0.67    
  E.  franqueti§ F A  0.05  0.16    
  E.  gambianus  F A  0.19  0.55    
  E.  gambianus  F  A  0.13 (1:50)  1.24 (1:800)     +
  E.  gambianus  F  SI  0.65 (1:200)  0.36 (1:50)    +  
Oyibi              
  June 2, 2007               
  E.  gambianus  M A  0.51  0.63    
Negative control (RAB691/d0)      0.19  0.27       
Positive control (RAB691/EBOV-N)      1.39  1.42    +  + 
*ZEBOV, Zaire Ebola virus; REBOV, Reston Ebola virus; OD, optical density; A, adult; SI, sexually immature.  
†Only serum samples with ZEBOV- or REBOV- positive ELISA results (optical density >0.50) were tested. 
‡Negative-control field serum samples. 
§Additional serum was not available for endpoint titer dilution determination. LETTERS
that the prevalence of EBOV in these 
tested bat species is greater than that 
previously detected in E. helvum bats 
(1/262 serum samples) (1). The higher 
estimated prevalence in these species 
occurred despite the fact that E. helvum 
bats live in large colonies comprising 
several million animals, which make 
the species an ideal host for acute 
RNA virus infections. The relatively 
low seroprevalence of EBOV among   
E. helvum bats compared with that 
among sympatric species is contrary 
to our ﬁ   ndings for a lyssavirus and 
an uncharacterized henipavirus 
(3,4). Our results, therefore, lead us 
to question what factors (e.g., host, 
ecologic) limit EBOV circulation 
in straw-colored fruit bats. Virus 
isolation is required to characterize 
EBOVs circulating among fruit bats 
in Ghana, and additional testing, 
including longitudinal sampling of 
bats, is required to further investigate 
the epidemiology of EBOV in West 
Africa. Possible public health threats 
should also be investigated and 
addressed. These initial ﬁ  ndings, 
however, suggest that the risk for 
human infection with EBOV might 
be greater from bat-human contact 
in rural and forest settings than from 
urban-roosting E. helvum bats.
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Outbreak-
associated Novel 
Duck Reovirus, 
China, 2011
To the Editor: In 2011, an 
unidentiﬁ   ed disease in Pekin ducks 
(Anas platyrhynchos) was reported 
in People’s Republic of China. The 
infection caused death in 40% of 
ducks of various age and 35%–40% 
mortality in different ﬂ  ocks. Clinical 
signs included unstable gait, weakness 
in legs, and diarrhea. At necropsy, 
large necrotic foci were observed in 
the spleens. All classical endemic 
and emerging viruses, such as duck 
enteritis virus, duck hepatitis virus, 
duck  ﬂ   avivirus, duck parvovirus, 
and avian inﬂ  uenza  virus,  could 
be excluded as the causative agent 
by PCR and serologic methods. To 
identify the cause of the disease, we 
tested tissue from affected ducks and 
subsequently isolated a novel duck-
pathogenic orthoreovirus from the 
livers of affected ducks.
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